The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...

Peter Guenter to retire as healthcare CEO, replaced by Danny Bar-Zohar; Matthias Heinzel steps down from life science unit.

If this CEO succeeds N-Power could save millions of dollars and lives in the fight against cancer. "The impact for cancer ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

DUBLIN (Reuters) - Ireland's foreign direct investment agency is hopeful that the impact of threatened U.S. tariffs on the country's large pharmaceutical sector will be limited by a U.S. desire to ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

Jean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.

Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases ---- Amit Munshi ...

Inhibikase Therapeutics (IKT) appointed Mark Iwicki as the company’s CEO, replacing Milton Werner, founder of Inhibikase, effective February ...

The German pharmaceutical-and-chemicals company on Tuesday said it appointed Jean-Charles Wirth as new chief executive of life science. Wirth succeeds Matthias Heinzel, who decided to not renew his ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...